BioCurex has pretty much had a self-imposed gag order since day One.

I am hoping for a surprise as much as anyone, but let's look at the past as a reference.

Last year, Biocurex had two announcements from ISOBM:

1) That Abbott and Biocurex were each able to separate Cancer and normal blood with a high degree of specificity using Serum-RECAF.

2) Point-of-care device looks promising.

What happened out of this was the securing of IMA as a licensee. I'm sure IMA did their due diligence.

Now we sit a year later.

Workshop 5: "RECAF as a Cancer Marker for Gastrointestinal Disease"

Is there any road to commercialization?